KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Capital Expenditures (2018 - 2025)

Historic Capital Expenditures for Takeda Pharmaceutical (TAK) over the last 8 years, with Q4 2025 value amounting to -$270.5 million.

  • Takeda Pharmaceutical's Capital Expenditures rose 879.91% to -$270.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.4 billion, marking a year-over-year increase of 3450.46%. This contributed to the annual value of $1.3 billion for FY2025, which is 836.95% up from last year.
  • As of Q4 2025, Takeda Pharmaceutical's Capital Expenditures stood at -$270.5 million, which was up 879.91% from -$272.1 million recorded in Q3 2025.
  • In the past 5 years, Takeda Pharmaceutical's Capital Expenditures ranged from a high of $2.3 billion in Q1 2025 and a low of -$369.0 million during Q2 2024
  • For the 5-year period, Takeda Pharmaceutical's Capital Expenditures averaged around $272.9 million, with its median value being -$271.3 million (2025).
  • Per our database at Business Quant, Takeda Pharmaceutical's Capital Expenditures surged by 2408.92% in 2022 and then crashed by 3446.16% in 2023.
  • Quarter analysis of 5 years shows Takeda Pharmaceutical's Capital Expenditures stood at -$238.2 million in 2021, then rose by 0.54% to -$236.9 million in 2022, then plummeted by 34.46% to -$318.5 million in 2023, then increased by 6.88% to -$296.6 million in 2024, then grew by 8.8% to -$270.5 million in 2025.
  • Its Capital Expenditures was -$270.5 million in Q4 2025, compared to -$272.1 million in Q3 2025 and -$331.1 million in Q2 2025.